Skip to main content
OpenTrials
Completed

NCT Number: NCT05861375

Liver Biomarkers in Anorexia Nervosa

The main goal of the Liver Biomarkers in Anorexia Nervosa (LIBAN) study is to determine the prevalence of liver fibrosis in patient with Anorexia Nervosa.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Anorexia Nervosa Digestive System Diseases Fatty Liver Feeding and Eating Disorders Fibrosis Liver Cirrhosis Liver Diseases Mental Disorders Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

15 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Nantes University Hospital

Nantes, Loire-Atlantique, 44093, France

About this study

Prevalence of hepatic fibrosis will be non-invasively investigated, in the Anorexia Nervosa inpatient population, using the Fibroscan ®. Furthermore, liver blood markers will be assessed.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient over 15 years old
  • Diagnosis of Restricted Eating Disorders including Anorexia Nervosa according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
  • Admission to the endocrinology, diabetology and nutrition department of the Nantes University Hospital.

Exclusion criteria

  • Chronic active viral hepatitis
  • Hemochromatosis
  • Other genetic, autoimmune, toxic or drug-induced hepatitis
  • Treatment with a drug known to induce fatty liver disease (amiodarone, carbamazepine, tamoxifen, valproate, clozapine, anti-retrovirals) unless the dose has been stable for ≥ 3 months
  • Excessive alcohol consumption (≥ 30 grams per day in men, ≥ 20 grams per day in women)

Treatment and study plan

FibroScan

Diagnostic Test

Fibroscan is a non-invasive device that allows liver exploration painlessly, quickly (a few minutes) and with immediate results. A probe placed on the skin generates an elastic wave completely painlessly and the device measures its speed of propagation in the liver. Liver stiffness is calculated from this speed.

Primary outcomes

  1. Liver fibrosis prevalence in patients with Anorexia nervosa

    Time frame: Day one

    Liver stiffness will be assessed using Fibroscan (kPA) within the 24 hours following admission to the endocrinology, diabetology and nutrition department.

Sponsors and collaborators

Lead sponsor

Nantes University Hospital

Other

Registry information

Official study title

Assessment of Liver Damage Using the Fibroscan in Patients With Anorexia Nervosa

Acronym: LIBAN

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
May 16, 2023
Registry last updated
Apr 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.